Antiplatelet and Antithrombotic Effects of the Extract of Lindera obtusiloba Leaves.
10.4062/biomolther.2016.021
- Author:
Jun Ho KIM
1
;
Jaemin LEE
;
Soouk KANG
;
Hongsik MOON
;
Kyung Ho CHUNG
;
Kyoung Rak KIM
Author Information
1. Research and Development Center, Han Wha Pharma. Co., Ltd., Chuncheon 24468, Republic of Korea. jungom@hwpharm.com
- Publication Type:Original Article
- Keywords:
Lindera obtusiloba;
Platelet aggregation;
Thrombosis;
Thromboxane
- MeSH:
Administration, Oral;
Animals;
Blood Platelets;
Cardiovascular Diseases;
Collagen;
Epinephrine;
Herbal Medicine;
In Vitro Techniques;
Inflammation;
Injections, Intravenous;
Lindera*;
Mice;
Partial Thromboplastin Time;
Platelet Aggregation;
Prothrombin Time;
Pulmonary Embolism;
Rats;
Thromboembolism;
Thrombosis;
Thromboxane A2
- From:Biomolecules & Therapeutics
2016;24(6):659-664
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lindera obtusiloba has been used in traditional herbal medicine for the treatment of blood stasis and inflammation. The leaves of Lindera obtusiloba have been reported to exhibit various physiological activities. However, there is little information available on their antiplatelet and antithrombotic activities. Thus, the present study aimed to evaluate the effect of Lindera obtusiloba leaf extract (LLE) on platelet activities, coagulation and thromboembolism. In a platelet aggregation study, LLE significantly inhibited various agonist-induced platelet aggregations in vitro and ex vivo. Furthermore, LLE significantly inhibited collagen-induced thromboxane A2 (TXA2) production in rat platelets. In addition, oral administration of LLE was protective in a mouse model of pulmonary thromboembolism induced by intravenous injection of a mixture of collagen and epinephrine. Interestingly, LLE did not significantly alter prothrombin time (PT) and activated partial thromboplastin time (aPTT). This study indicates that the antithrombotic effects of LLE might be due to its antiplatelet activities rather than anticoagulation. Taken together, these results suggest that LLE may be a candidate preventive and therapeutic agent in cardiovascular diseases associated with platelet hyperactivity.
